Literature DB >> 8186065

The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretion.

C A Verhagen1, H Mattie, E Van Strijen.   

Abstract

1. The renal tubular excretion of cefuroxime and ceftazidime in relation to the coadministration of probenecid was investigated in eight and two healthy subjects, respectively. 2. Cefuroxime or ceftazidime were administered by i.v. infusion and 1 g probenecid was administered orally after steady state plasma concentrations of the cephalosporin were reached. 3. In a second session the same antibiotic was administered at increasing infusion rates such that three different levels of plasma drug concentration were achieved. 4. The renal clearance of antibiotic was calculated based upon unbound plasma concentration, and tubular clearance was estimated by subtracting inulin clearance from the renal clearance of the antibiotic. 5. Non-linear regression analysis was used to estimate parameters describing the saturability of tubular excretion and the effect of probenecid inhibition, i.e. EC50 and Rtub,max, could be established for cefuroxime: EC50 was 248 (s.d. 130) mg l-1 and Rtub,max was 1.852 (s.d. 0.577) mg h-1. Tubular excretion of ceftazidime was practically zero. The EC50 of probenecid for inhibition of the tubular excretion of cefuroxime was 0.80 (s.d. 0.31) mg l-1. 6. The results indicate that in the therapeutic plasma concentration range of cefuroxime its renal clearance is not saturated. Probenecid at therapeutic doses will block tubular excretion of cefuroxime almost completely.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8186065      PMCID: PMC1364597          DOI: 10.1111/j.1365-2125.1994.tb04260.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  A new method for the determination of inulin in plasma and urine.

Authors:  A HEYROVSKY
Journal:  Clin Chim Acta       Date:  1956 Sep-Oct       Impact factor: 3.786

2.  The effect of probenecid on the renal tubular excretion of benzylpenicillin.

Authors:  D Overbosch; C Van Gulpen; J Hermans; H Mattie
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

3.  Saturation of the tubular excretion of beta-lactam antibiotics.

Authors:  J W Bins; H Mattie
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

4.  Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

Authors:  R Lüthy; J Blaser; A Bonetti; H Simmen; R Wise; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

Review 5.  Renal tubule transport of organic cations.

Authors:  B R Rennick
Journal:  Am J Physiol       Date:  1981-02

6.  The relative potency of amoxycillin and ampicillin in vitro and in vivo.

Authors:  H Mattie; G B van der Voet
Journal:  Scand J Infect Dis       Date:  1981

Review 7.  Cefuroxime: a review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-04       Impact factor: 9.546

Review 8.  Pharmacokinetic properties of the cephalosporins.

Authors:  T Bergan
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 9.  Clinical pharmacokinetics of probenecid.

Authors:  R F Cunningham; Z H Israili; P G Dayton
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

View more
  7 in total

1.  Clinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion.

Authors:  J Berkhout; L G Visser; P J van den Broek; J A M van de Klundert; H Mattie
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

2.  Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.

Authors:  André Dallmann; Ibrahim Ince; Juri Solodenko; Michaela Meyer; Stefan Willmann; Thomas Eissing; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

3.  An Overview of the Protein Binding of Cephalosporins in Human Body Fluids: A Systematic Review.

Authors:  C Jongmans; A E Muller; P Van Den Broek; B De Melo Cruz De Almeida; C Van Den Berg; J Van Oldenrijk; P K Bos; B C P Koch
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

4.  Once-daily versus twice-daily administration of ceftazidime in the preterm infant.

Authors:  J N van den Anker; R C Schoemaker; B J van der Heijden; H M Broerse; H J Neijens; R de Groot
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

5.  Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8).

Authors:  Sook Wah Yee; Anh Nguyet Nguyen; Chaline Brown; Radojka M Savic; Youcai Zhang; Richard A Castro; Cheryl D Cropp; Ji Ha Choi; Diment Singh; Harunobu Tahara; Sophie L Stocker; Yong Huang; Claire M Brett; Kathleen M Giacomini
Journal:  J Pharm Sci       Date:  2013-05-06       Impact factor: 3.534

Review 6.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

7.  PBPK Modeling Approach to Predict the Behavior of Drugs Cleared by Kidney in Pregnant Subjects and Fetus.

Authors:  Ke Xu Szeto; Maxime Le Merdy; Benjamin Dupont; Michael B Bolger; Viera Lukacova
Journal:  AAPS J       Date:  2021-06-24       Impact factor: 4.009

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.